AU2005224061B2 - Use of a 5-HT3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain - Google Patents
Use of a 5-HT3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain Download PDFInfo
- Publication number
- AU2005224061B2 AU2005224061B2 AU2005224061A AU2005224061A AU2005224061B2 AU 2005224061 B2 AU2005224061 B2 AU 2005224061B2 AU 2005224061 A AU2005224061 A AU 2005224061A AU 2005224061 A AU2005224061 A AU 2005224061A AU 2005224061 B2 AU2005224061 B2 AU 2005224061B2
- Authority
- AU
- Australia
- Prior art keywords
- cilansetron
- group
- abdominal
- treatment
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011282 treatment Methods 0.000 title claims description 31
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims description 20
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 title claims description 17
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 title claims description 17
- 239000003814 drug Substances 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 208000002193 Pain Diseases 0.000 title description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 title description 6
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 claims description 36
- 229960002099 cilansetron Drugs 0.000 claims description 36
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 31
- 201000009273 Endometriosis Diseases 0.000 claims description 27
- 208000000450 Pelvic Pain Diseases 0.000 claims description 21
- 208000004998 Abdominal Pain Diseases 0.000 claims description 13
- 238000011321 prophylaxis Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 9
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 claims description 9
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 claims description 9
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims description 9
- 229960003550 alosetron Drugs 0.000 claims description 9
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims description 9
- 229950005951 azasetron Drugs 0.000 claims description 9
- 229950007840 bemesetron Drugs 0.000 claims description 9
- MNJNPLVXBISNSX-WDNDVIMCSA-N bemesetron Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-WDNDVIMCSA-N 0.000 claims description 9
- ILXWRFDRNAKTDD-QDMKHBRRSA-N chembl2105377 Chemical compound C1C(C)(C)C2=CC=CC=C2N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C ILXWRFDRNAKTDD-QDMKHBRRSA-N 0.000 claims description 9
- SPKBYQZELVEOLL-QDMKHBRRSA-N chembl2111147 Chemical compound N([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-QDMKHBRRSA-N 0.000 claims description 9
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims description 9
- 229960003413 dolasetron Drugs 0.000 claims description 9
- AEKQMJRJRAHOAP-CYBMUJFWSA-N fabesetron Chemical compound N1C=NC(C[C@@H]2C(N3C4=CC=CC=C4C(C)=C3CC2)=O)=C1C AEKQMJRJRAHOAP-CYBMUJFWSA-N 0.000 claims description 9
- 229950004275 fabesetron Drugs 0.000 claims description 9
- 229960003727 granisetron Drugs 0.000 claims description 9
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 9
- 229950007467 indisetron Drugs 0.000 claims description 9
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 claims description 9
- 229950007654 itasetron Drugs 0.000 claims description 9
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 claims description 9
- 229950009727 lerisetron Drugs 0.000 claims description 9
- 229960005343 ondansetron Drugs 0.000 claims description 9
- 229960002131 palonosetron Drugs 0.000 claims description 9
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims description 9
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 claims description 9
- 229950001588 ramosetron Drugs 0.000 claims description 9
- 229950005271 ricasetron Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 229960003688 tropisetron Drugs 0.000 claims description 9
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims description 9
- 229950004681 zacopride Drugs 0.000 claims description 9
- 229950001074 zatosetron Drugs 0.000 claims description 9
- ZRIRTEMBXFFOGF-GFCCVEGCSA-N (3r)-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound N1C=NC(C[C@@H]2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C ZRIRTEMBXFFOGF-GFCCVEGCSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229950000139 galdansetron Drugs 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- NUMKWGDDRWJQMY-UHFFFAOYSA-N lurosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=C(F)C=CC=C43)C)CC2)=O)=C1C NUMKWGDDRWJQMY-UHFFFAOYSA-N 0.000 claims description 6
- 229950009334 lurosetron Drugs 0.000 claims description 6
- JXQUEAGLZNCBHC-QCUBGVIVSA-N cilansetron hydrochloride Chemical compound O.Cl.CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 JXQUEAGLZNCBHC-QCUBGVIVSA-N 0.000 claims description 5
- -1 gaidansetron Chemical compound 0.000 claims description 4
- 201000003146 cystitis Diseases 0.000 description 27
- 210000003932 urinary bladder Anatomy 0.000 description 22
- 229960004397 cyclophosphamide Drugs 0.000 description 13
- 229940044551 receptor antagonist Drugs 0.000 description 13
- 239000002464 receptor antagonist Substances 0.000 description 13
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 12
- 102000035037 5-HT3 receptors Human genes 0.000 description 10
- 108091005477 5-HT3 receptors Proteins 0.000 description 10
- QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 10
- 108700023918 icatibant Proteins 0.000 description 10
- 230000008602 contraction Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 201000007094 prostatitis Diseases 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027566 Micturition urgency Diseases 0.000 description 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 2
- 229920003080 Povidone K 25 Polymers 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010065951 Retrograde menstruation Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007360 epithelial dysfunction Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 208000036366 Sensation of pressure Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010050822 Suprapubic pain Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003796 diagnosis of exclusion Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
WO 2005/089732 PCT/EP2005/051263 USE OF A 5-HT3 RECEPTOR ANTAGONIST FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF NON-DIGESTIVE TRACT DERIVED ABDOMINAL DISORDERS ASSOCIATED WITH PAIN The present invention relates to a novel medicinal use of 5-HT 3 receptor antagonists, in particular cilansetron, or their pharmacologically compatible derivatives like salts and/or solvates, f or the treatment and/or prophylaxis of non-digestive tract derived abdominal disorders associated with pain, in particular Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with endometriosis. Regarding the therapeutic potential of 5-HT 3 receptor antagonists, it is already widely known that those can play a beneficial role in i.a. the treatment of gastrointestinal disorders (see e.g. Z.H. Israili, Curr. Med. Chem. - CNS Agents 1 (2001) 171-199 for a review). From EP 0 467 365 A2 the use of 5-HT 3 receptor antagonists for the treatment of urinary incontinence is already known. Johansen et al. (see Current Opinion in Urology, _12/1 (2002) 63-67, cited as "Johansen et al." hereinafter) are discussing a relation between the possible aetiological role of mast cells in Interstitial Cystitis and the importance of serotonin as a therapeutic agent in Interstitial Cystitis and Chronic Pelvic Pain Syndrome. Of non-digestive tract derived abdominal disorders associated with pain, Interstital Cystitis, Chronic Pelvic Pain Syndrome and abdominal pain associated with endometrio sis may best be cured by administration of 5-HT 3 receptor antagonists. Therapy of Inter stitial Cystitis is preferred. According to the invention, "therapy" is meant to comprise both, prophylaxis and treatment of a disorder. Interstitial Cystitis is a chronic disorder of the urinary bladder characterised by symptoms of urinary frequency and urgency, suprapubic pain, dyspareunia (anticipation of pain during sexual intercourse), nocturia and chronic pelvic pain (see e.g. G. Newsome, Journal of the American Academy of Nurse Practitioners, 15(2) (2003) 64-71). Interstitial Cystitis occurs primarily in women but also in men. Several pathophysiological mechanisms have been proposed in the past few years including epithelial dysfunction, WO 2005/089732 PCT/EP2005/051263 2 activation of mast cells, neurogenic inflammation, autoimmunity, occult (viral or bacterial) infection, toxin exposure and pelvic floor dysfunction. Onset of Interstitial Cystitis is pre dominately in adulthood although it does occur in childhood. The prevalence of Interstitial Cystitis has ranged from about 8 - 60 cases/100,000 female patients depending on the population evaluated. About 10% of patients have severe symptoms that are associated with Hunner's ulcers on bladder biopsy; the rest could be grouped in those with or without bladder inflammation. Interstitial Cystitis in men is probably underdiagnosed and is most commonly misdiagnosed as prostatitis. Symptoms of Interstitial Cystitis are exac erbated by stress, certain foods and ovulatory hormones. Many patients also experience allergies, irritable bowel syndrome (IBS) and migraines. There have been various reports indicating dysfunction of the bladder glycosaminoglycan (GAG) protective layer and ma ny publications showing a high number of activated bladder mast cells. Diagnosis is by history, physical examination, laboratory tests, and cystoscopic ex amination; it thus largely remains a diagnosis of exclusion. Approved treatments so far include intravesical administration of dimethylsulphoxide (DMSO) or oral pentosanpoly sulphate (PPS) but today's management of Interstitial Cystitis also may include dietary changes, antihistamines, tricyclic antidepressants, oral and intravesicle glucosaminogly cans, hydrodistention, pain management and emotional support. Criteria for diagnosis of Interstitial Cystitis have been established by the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (Gillenwater et al. J. Urol 14Q (1988) 203-208). These include glomerulations or Hunner's Ulcer on cystoscopic examination and pain associ ated with bladder or urinary urgency. Recently, Interstitial Cystitis is often divided into two subtypes: classical and nonulcer disease (Peeker and Fall J. Urol. 167 (2002) 2470 2472). Chronic Pelvic Pain Syndrome is a syndrome often related to Interstitial Cystitis. According to the classification of the US National Institiute of Health as "Type Ill Prostati tis" (see J.N. Krieger et al., JAMA 22 (1999) 236-237) it is to be regarded as a chronic, abacterial prostatitis. Patients with non-inflammatory Chronic Pelvic Pain Syndrome are the largest group of prostatitis patients according to the US National Institute of of Diabe tes and Digestive and Kidney Diseases classification and are characterized by the ab sence of objective findings. Interestingly, for the majority of patients, no objective find ings link the symptoms of prostatitis to the prostate gland or to the male genital tract and thus, no findings seem to link the symptoms of Chronic Pelvic Pain Syndrome to the male in particular. Mounting evidence instead suggests, that a significant overlap may exist between Interstitial Cystitis and Chronic Pelvic Pain Syndrome in epidemiology, WO 2005/089732 PCT/EP2005/051263 3 pathophysiology and even therapy. In fact, both conditions might represent different manifestations of the same disease process. For example, very similar theories of pathogenesis exist for both conditions: occult infections, epithelial dysfunction, neuro genic inflammation mast cell activation and autoimmunity are features that seem to play a role in the formation of Interstital Cystitis as well as in the formation of Chronic Pelvic Pain Syndrome (see e.g. Johansen et al.; R.M. Moldwin, Current Urology Reports 3/4 (2002) 313-318). Similar medications for both conditions will therefore seem promising. For a review on Chronic Pelvic Pain Syndrome see for example M. McNaughton-Collins et al., Ann. Intern. Med. 133 (2000) 367-381. Endometriosis is a well-known gynaecological disorder that affects 10 to 15% of women in the reproductive age. It is a benign disease defined as the presence of viable uterine tissue, e.g. endometrial gland and stroma cells outside the uterine cavity. It is most frequently found in the pelvic area, in particular in the ovaries. In women developing endometriosis, the endometrial cells entering the peritoneal cavity by retrograde men struation (the most likely mechanism) have the capacity to adhere to and invade the peri toneal lining, and are then able to implant and grow. The implants respond to steroid hormones of the menstrual cycle in a similar way as the endometrium in the uterus. The infiltrating lesions and the blood from these lesions which are unable to leave the body cause inflammation of the surrounding tissue. The most common symptoms of endome triosis are dysmenorrhoea, dyspareunia and (chronic) abdominal pain. The occurrence of these symptoms is not related to the extent of the lesions. Some women with severe endometriosis are asymptomatic, while women with mild endometriosis may have severe pain. Up to now, no reliable and easy to use non-invasive test is available to diagnose endometriosis. Laparoscopy has to be performed to diagnose the disease. Endometrio sis is classified according to the 4 stages set up by the American Fertility Society (AFS). Stage I corresponds to minimal disease while stage IV is severe, depending on the loca tion and the extent of the endometriosis. Endometriosis is found in up to 50% of the women with infertility. However, currently no causal relation has been proven between mild endometriosis and infertility. Moderate to severe endometriosis can cause tubal damage and adhesions leading to infertility. Despite extensive research, the cause of endometriosis is still largely unknown. Several theories for the origin of endometriosis have been proposed, although no single hypothesis explains all cases of the disease completely. However, the key event in all these theories seems to be the occurrence of retrograde menstruation. The aims of treatment of endometriosis are currently pain relief, resolution of the endometriotic tissue and restoration of fertility (if desired). The two com- 4 mon treatments are surgery or anti-inflammatory and/or hormonal therapy or a combination thereof. It has now surprisingly been discovered that 5-HT 3 receptor antagonists can serve as treatment and/or prophylaxis for non-digestive tract derived abdominal disorders associated 5 with pain, in particular Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with endometriosis. The object of the invention is thus the novel use of a 5-HT 3 receptor antagonist or a pharmacologically compatible derivative thereof like a salt and/or a solvate, for the treatment and/or prophylaxis of non-digestive tract derived abdominal disorders associated with pain, 10 in particular Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with endometriosis, in larger mammals and humans. The present invention is directed to: e use of a 5-HT 3 receptor antagonist selected from the group consisting of alosetron, azasetron, bemesetron, cilansetron, dolasetron, fabesetron, galdansetron, granisetron, 15 indisetron, itasetron, lerisetron, Jurosetron, ondansetron, palonosetron, ramosetron, ricasetron, tropisetron, zacopride and zatosetron, or a pharmacologically compatible derivative thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with 20 endometriosis; e a method of treatment of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with endometriosis which method comprises administering an effective amount of a 5
HT
3 receptor antagonist selected from the group consisting of alosetron, azasetron, 25 bemesetron, cilansetron, dolasetron, fabesetron, galdansetron, granisetron, indisetron, itasetron, lerisetron, lurosetron, ondansetron, palonosetron, ramosetron, ricasetron, tropisetron, zacopride and zatosetron, or a pharmacologically compatible derivative thereof, to a person in need of such treatment; e a 5-HT 3 receptor antagonist selected from the group consisting of alosetron, azasetron, 30 bemesetron, cilansetron, dolasetron, fabesetron, galdansetron, granisetron, indisetron, itasetron, lerisetron, lurosetron, ondansetron, palonosetron, ramosetron, ricasetron, tropisetron, zacopride and zatosetron, or a pharmacologically compatible derivative thereof, when used for the treatment and/or prophylaxis of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome 35 and/or abdominal pain associated with endometriosis; 4a 0 a 5-HTa receptor antagonist selected from the group consisting of alosetron, azasetron, bemesetron, cilansetron, dolasetron, fabesetron, galdansetron, granisetron, indisetron, itasetron, lerisetron, Furosetron, ondansetron, palonosetron, ramosetron, ricasetron, tropisetron, zacopride and zatosetron, or a pharmacologically compatible derivative 5 thereof, when used for the treatment and/or prophylaxis of an abdominal disorder, which is Interstitial Cystitis; and * a 5-HT 3 receptor antagonist or a pharmacologically compatible derivative thereof when used for the treatment and/or prophylaxis of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal 10 pain associated with endometriosis, wherein the 5-HT 3 receptor antagonist is cilansetron or a pharmacologically compatible acid addition salt and/or a solvate thereof. Suitable 5-HT 3 receptor antagonists according to the invention are in particular selected from the group consisting of alosetron, azasetron, bemesetron, cilansetron, dolasetron, 15 fabesetron, galdansetron, granisetron, indisetron, itasetron, lerisetron, lurosetron, ondansetron, palonosetron, ramosetron, ricasetron, tropisetron, zacopride and zatosetron. Cilansetron is the preferred 5-HT 3 receptor antagonist. Cilansetron comes within the scope of European Patent EP 0 297 651 B1 and has the chemical name (R)-(-)-4,5,6,8,9,10 hexahydro-1 0-[(2-methyl-1 H-imidazol-1 -yl)methyl]-1 1 H-pyrido-[3,2, 1 -jk]-carbazol-1 1-one. 20 Cilansetron may preferably be used in the form of its hydrochloride. Usually, cilansetron hydrochloride monohydrate is used. Further pharmacologically compatible acid addition salts of cilansetron are known from e.g. EP 0 297 651 B1. The beneficial influence of 5-HT 3 receptor antagonists according to the invention can be demonstrated e.g. by an in vivo animal test model predictive for the therapeutic potential 25 of test compounds in non-digestive tract derived abdominal disorders associated with pain, in particular of Interstitial Cystitis. In this test model, the effect of 5-HT 3 receptor antagonists on rats with cyclophosphamide-induced cystitis was investigated. Inflammation of the bladder responsible for bladder overactivity was induced by an intraperitoneal (i.p.) cyclophosphamide injection (150 mg/kg, i.p.) 48h before testing (Maggi 30 et al., J Auton Nerv Syst 38 (1992) 201) using male Wistar rats weighing 300-350 g. Rats were anesthetized with urethane delivered subcutaneously in saline (1.2 g/kg) and their temperature was maintained at 37 0 C. Following a midline abdominal incision a WO 2005/089732 PCT/EP2005/051263 5 catheter was inserted through the bladder dome and sealed with a tie. The catheter was connected via a T-tube to a pressure transducer and a syringe pump, to allow filling of the bladder with warm (37*C) saline at 50 pl/min simultaneously with recording of i n travesical pressure. This catheter was later used for cystometry. For each voiding and non-voiding contraction, the threshold pressure (ThP, corre sponding to the bladder pressure at the onset of the voiding contraction (mm Hg), the maximal voiding pressure (MP, defined by the maximal bladder pressure reached during voiding contraction (mm Hg)) the basal pressure (BaP, defined by the lowest bladder pressure reached after the voiding contraction (mm Hg) and the area under the curve of the bladder pressure (AUP) during voiding (mm Hg x s) was calculated for each rat and averaged for each condition. In addition, the frequency of contractions was determined. Test groups consisting of 10 rats each were used. Drug treatments were performed as described in the following table 1. Table 1: Group design for test model of 5-HT 3 receptor antagonists on rats with cyclo phosphamide-induced cystitis Group Pretreatment 48 h be- Acute treatment fore acute treatment I (control) vehicle vehicle 2 (cystitis control) Cyclophosphamide vehicle 150 mg/kg i.p. 3 (cystitis + reference compound) Cyclophosphamide HOE140 130 pg/kg i.v 150 mg/kg i.p. 4 (cystitis + cilansetron 0.01 mg/kg Cyclophosphamide Cilansetron 0.01 mg/kg i.v. i.v.) 150 mg/kg i.p. 5 (cystitis + cilansetron 0.1 mg/kg i.v.) Cyclophosphamide Cilansetron 0.1 mg/kg i.v. 150 mg/kg i.p. In groups 2-5 cystitis was induced by cyclophosphamide 150 mg/kg intraperito neally (i.p.) 48h before the experiment; group 1 served as a control group. Drugs or ve- WO 2005/089732 PCT/EP2005/051263 6 hicle to be tested were injected 10 minutes before the beginning of cystometry. Besides three doses of cilansetron (group 4-5), HOE 140 (D-Arginyl-[Hyp3, Thi5, D-Tic7, Oic8] bradykinin), a bradykinin 2 receptor antagonist, was used as a reference standard known to be active in this model. During the cystometry the pressure changes due to transvesi cal perfusion of warm saline at 50 pl/min were recorded over 60 minutes. Parameters (as outlined above) were analysed for each bladder filling. Cyclophosphamide pretreatment consistently changed all parameters of cystometry but micturition pressure. Compared to the vehicle control group (group 1) the basal pres sure, threshold pressure and frequency of bladder contraction in the cystitis group were consistently increased in the cystitis group (group 2) (see Table 2), whereas the area under the curve of the bladder contractions as well as the volume of perfusion at the on set of the 1 st micturition was consistently decreased in the cystitis group (group 2) (see Table 2) Thus cystitis resulted in decreased bladder compliance (i.e. greater bladder pressures were reached with smaller volumes of perfusion) and bladder overactivity. Table 2:: Effects of test compounds in rats with cyclophosphamide-induced cystitis group I group 2 group 3 group 4 group 5 cyclophos- cyclophos cyclophos phamide phamide phamide cyclophos- cystitis + cystitis + cystitis phamide cilansetron cilansetron vehicle control cystitis + 0.01 mg/kg 0.1 mg/kg control HOE140 i.v. t.v. basal pressure [mmHg] 13 19 16 16 14 threshold pressure [mmHg] 15 20 17 17 15 frequency hourss] 15 35 30 26 28 Treatment with HOE140 decreased the cystitis induced changes basal pressure and threshold pressure, as well as frequency of bladder contractions by 50, 60 and 25%, respectively (see Tables 2 and 3). Micturition pressure area under the curve and 1 It mic turition volume were not affected by HOE140 treatment. It can be concluded that HOE140 partially alleviated some of the effects of cystitis as it changed key parameters of micturition towards values observed in the control group.
WO 2005/089732 PCT/EP2005/051263 7 Table 3: Inhibition of cystitis effects % inhibition of cystitis effects group 3 group 4 group 5 cyclophos- cyclophos phamide phamide cyclophos- cystitis + cystitis + phamide cysti- cilansetron cilansetron tis + HOE140 0.01 mg/kg iv. 0.1 mg/kg iv. basal pressure 50 50 83 threshold pressure 60 60 100 freuency 25 45 35 Treatment with cilansetron in a concentration as low as 0.01 mg/kg iLv. decreased cystitis induced changes in basal pressure and threshold pressure, as well as frequency of bladder contractions by 50, 60 and 45%, respectively (see Tables 2 and 3). Thus, it was similarly effective as or even more effective than the reference compound HOE 140. At 0.1 mg/kg Lv. cilansetron was even more potent in decreasing the cystitis evoked changes in basal pressure and threshold pressure by 83 and 100% respectively (see Tables 2 and 3). Acute treatment with HOE140 130 pg/kg reduced the symptoms of bladder overac tivity associated with cyclophosphamide pretreatment. The dosing of 0.01 and 0.1 mg/kg cilansetron reduced these symptoms to an equivalent or slightly greater extent. Thus in the foregoing animal test model on cystometry in rats with cyclophosphamide-induced cystitis, cilansetron showe d a beneficial effect even superior to the effect caused by HOE140. As therapeutic agents, the 5-HT 3 receptor antagonists or their pharmacologically compatible acid addition salts and/or their solvates may be administered in conventional pharmaceutical preparations. In an individual case, special dosage forms may be indi cated. The doses to be used may vary individually and will naturally vary according to the type of condition to be treated and the substance used. In general, however, medicinal forms with an active substance content of 0.2 to 200 mg, in particular I to 50 mg, active substance per individual dose are suitable for administration to humans and larger mam mals. The compounds may be contained according to the invention, together with con ventional pharmaceutical auxiliaries and/or carriers, in solid or liquid pharmaceutical preparations. Examples of solid preparations are preparations which can be adminis tered orally, such as tablets, coated tablets, capsules, powders or granules, or alterna- WO 2005/089732 PCT/EP2005/051263 8 tively suppositories. These preparations may contain conventional pharmaceutical inor ganic and/or organic carriers, such as talcum, lactose or starch, in addition to conven tional pharmaceutical auxiliaries, for example lubricants or tablet disintegrating agents. Liquid preparations such as suspensions or emulsions of the active substances may con tain the usual diluents such as water, oils and/or suspension agents such as polyethyl ene glycols and the like. Other auxiliaries may additionally be added, such as preserva tives, taste correctives and the like. A 5-HT 3 receptor antagonist or a pharmacologically compatible acid addition salt and/or a solvate thereof, preferably cilansetron, can be mixed and formulated with the pharmaceutical auxiliaries and/or carriers in known manner. For the production of solid medicament forms, cilansetron or its acid addition salt can for example be mixed with the auxiliaries and/or carriers in conventional manner and can be wet or dry granulated. The granules or powder can be poured directly into capsules or be pressed into tablet cores in conventional manner. These can be coated in known manner if desired. The following example is intended to explain the production of pharmaceutical preparations containing cilansetron hydrochloride. Example I: Tablets containing cilansetron Composition: Cilansetron hydrochloride monohydrate 4 parts Corn starch 30 parts Lactose 70 parts Kollidon 25@ 5 parts Magnesium stearate 2 parts Talcum 3 parts Total: 114 parts Preparation procedure: The active substance was mixed with corn starch and fine-powdered lactose in a mixer. The resulting mixture was moistened thoroughly with a 20% solution of polyvinylpyrroli done (Kollidon 25@ by BASF) in demineralised water. If necessary, further demineralised water was added. The moist granules were passed through a 2 mm sieve, dried on trays at 40 0 C and then passed through a 1 mm sieve (Frewitt machine). Once the granules had been mixed with magnesium stearate and talcum, tablets of a weight of 114 mg were pressed therefrom, so that each tablet contained 4 mg active substance.
9 Likewise or preferably, other pharmaceutical preparations of cilansetron may be used, for example stabilised pharmaceutical preparations known from EP 0 895 782 A2. Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or 5 components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
Claims (12)
1. A use of a 5-HT 3 receptor antagonist selected from the group consisting of alosetron, azasetron, bemesetron, cilansetron, dolasetron, fabesetron, galdansetron, 5 granisetron, indisetron, itasetron, lerisetron, lurosetron, ondansetron, palonosetron, ramosetron, ricasetron, tropisetron, zacopride and zatosetron, or a pharmacologically compatible derivative thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with 10 endometriosis.
2. A use according to claim 1 wherein the abdominal disorder is Interstitial Cystitis.
3. Use according to claim 1 wherein the 5-HT 3 receptor antagonist is cilansetron or a pharmacologically compatible acid addition salt and/or a solvate thereof.
4. Use according to claim 3 of cilansetron hydrochloride. 15
5. Use according to claim 4 of cilansetron hydrochloride monohydrate.
6. A method of treatment of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with endometriosis which method comprises administering an effective amount of a 5-HT 3 receptor antagonist selected from the group consisting of alosetron, azasetron, bemesetron, 20 cilansetron, dolasetron, fabesetron, galdansetron, granisetron, indisetron, itasetron, lerisetron, lurosetron, ondansetron, palonosetron, ramosetron, ricasetron, tropisetron, zacopride and zatosetron, or a pharmacologically compatible derivative thereof, to a person in need of such treatment.
7. A method according to claim 6 wherein the abdominal disorder is Interstitial Cystitis. 25
8. A method according to claim 6 or claim 7, wherein the 5-HT 3 receptor antagonist is cilansetron or a pharmacologically compatible acid addition salt and/or a solvate thereof.
9. A 5-HT 3 receptor antagonist selected from the group consisting of alosetron, azasetron, bemesetron, cilansetron, dolasetron, fabesetron, galdansetron, granisetron, indisetron, itasetron, lerisetron, lurosetron, ondansetron, palonosetron, ramosetron, 30 ricasetron, tropisetron, zacopride and zatosetron, or a pharmacologically compatible derivative thereof, when used for the treatment and/or prophylaxis of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with endometriosis. 11
10. A 5-HT 3 receptor antagonist selected from the group consisting of alosetron, azasetron, bemesetron, cilansetron, dolasetron, fabesetron, gaidansetron, granisetron, indisetron, itasetron, lerisetron, Jurosetron, ondansetron, palonosetron, ramosetron, ricasetron, tropisetron, zacopride and zatosetron, or a pharmacologically compatible 5 derivative thereof, when used for the treatment and/or prophylaxis of an abdominal disorder, which is Interstitial Cystitis.
11. A 5-HT 3 receptor antagonist or a pharmacologically compatible derivative thereof when used for the treatment and/or prophylaxis of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain 10 associated with endometriosis, wherein the 5-HT 3 receptor antagonist is cilansetron or a pharmacologically compatible acid addition sait and/or a solvate thereof.
12. A method of treatment of an abdominal disorder selected from the group consisting of Interstitial Cystitis, Chronic Pelvic Pain Syndrome and/or abdominal pain associated with endometriosis which method comprises administering an effective amount .5 of tablet(s) containing cilansetron, wherein the tablet(s) are substantially as hereinbefore described with reference to Example 1. SOLVAY PHARMACEUTICALS GMBH 0 WATERMARK PATENT AND TRADE MARKS ATTORNEYS P27536AUOO
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04101135.4 | 2004-03-19 | ||
EP04101135 | 2004-03-19 | ||
PCT/EP2005/051263 WO2005089732A1 (en) | 2004-03-19 | 2005-03-18 | Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2005224061A1 AU2005224061A1 (en) | 2005-09-29 |
AU2005224061B2 true AU2005224061B2 (en) | 2011-01-27 |
Family
ID=34928913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005224061A Ceased AU2005224061B2 (en) | 2004-03-19 | 2005-03-18 | Use of a 5-HT3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1727527A1 (en) |
JP (1) | JP2007529476A (en) |
CN (1) | CN1925846B (en) |
AU (1) | AU2005224061B2 (en) |
BR (1) | BRPI0508972A (en) |
CA (1) | CA2560279A1 (en) |
WO (1) | WO2005089732A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0279512B1 (en) * | 1987-01-19 | 1996-03-27 | Beecham Group Plc | Use of certain 5-HT3 receptor antagonists in the treatment of visceral pain |
AU2004227945A1 (en) * | 2003-04-04 | 2004-10-21 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1284732A2 (en) * | 2000-05-18 | 2003-02-26 | Glaxo Group Limited | Method for treating functional dyspepsia using alosetron |
WO2004006902A1 (en) * | 2002-07-10 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
-
2005
- 2005-03-18 CA CA002560279A patent/CA2560279A1/en not_active Abandoned
- 2005-03-18 CN CN2005800066629A patent/CN1925846B/en not_active Expired - Fee Related
- 2005-03-18 EP EP05717101A patent/EP1727527A1/en not_active Withdrawn
- 2005-03-18 JP JP2007503356A patent/JP2007529476A/en active Pending
- 2005-03-18 WO PCT/EP2005/051263 patent/WO2005089732A1/en not_active Application Discontinuation
- 2005-03-18 AU AU2005224061A patent/AU2005224061B2/en not_active Ceased
- 2005-03-18 BR BRPI0508972-7A patent/BRPI0508972A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0279512B1 (en) * | 1987-01-19 | 1996-03-27 | Beecham Group Plc | Use of certain 5-HT3 receptor antagonists in the treatment of visceral pain |
AU2004227945A1 (en) * | 2003-04-04 | 2004-10-21 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
Also Published As
Publication number | Publication date |
---|---|
WO2005089732A1 (en) | 2005-09-29 |
CN1925846A (en) | 2007-03-07 |
EP1727527A1 (en) | 2006-12-06 |
CN1925846B (en) | 2011-11-16 |
BRPI0508972A (en) | 2007-08-28 |
AU2005224061A1 (en) | 2005-09-29 |
JP2007529476A (en) | 2007-10-25 |
CA2560279A1 (en) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Alwan et al. | Angiotensin II receptor antagonist treatment during pregnancy | |
Yildirim et al. | The effects of letrozole and melatonin on surgically induced endometriosis in a rat model: a preliminary study | |
US20050131049A1 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | |
EP2109449B1 (en) | Medicament for the treatment of endometriosis | |
US20080108596A1 (en) | Combination of Quetiapine and Zolmitriptan | |
US7820690B2 (en) | Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist | |
AU2005224061B2 (en) | Use of a 5-HT3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain | |
JP6612233B2 (en) | Use of PAR-1 antagonists to prevent and / or treat pathological conditions of pelvic / perineal function | |
MXPA06009840A (en) | Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain | |
Li et al. | Bushen Wenyang Huayu Decoction Targets TLR4/NF-κB Mediated Autophagy to Treat Endometriosis Effectively | |
US20100305210A1 (en) | S-alkylisothiouronium derivatives for treating abnormal uterine bleeding disorders | |
RU2321398C2 (en) | Treatment method | |
AU2002326271A1 (en) | A combination of quetiapine and zolmitriptan | |
RU2805061C2 (en) | Treatment of demyelinating diseases | |
CN116570593B (en) | Medicine for preventing premature ovarian failure and application thereof | |
US20060128738A1 (en) | Treatment of interstitial cystitis using cannabinoid analogs | |
EP3811942A1 (en) | Use of tyrosine hydroxylase inhibitors for the treatment of aortic aneurysm | |
JP4925406B2 (en) | Preventive and / or therapeutic agent for diabetic nephropathy | |
JP2010536808A (en) | Use of genestagen in combination with (6S) -5-methyltetrahydrofolic acid to treat endometriosis while reducing therapeutic side effects and further reducing the risk of congenital abnormalities after pregnancy. | |
WO2021046446A1 (en) | Compositions and methods of use for enhancing fertility | |
Li et al. | Analysis of the Clinical Effects of Different Methods for Preventing the Postoperative Recurrence of Ovarian Endometriosis | |
WO2023228204A1 (en) | Clomipramine for the treatment of alzheimer's disease | |
WO2024033946A1 (en) | Compositions and use in methods for treating a cognitive deficit | |
RU2253457C2 (en) | Urogenital infection treatment drug | |
Ali et al. | Clinical efficacy of Anisoon (Pimpinella anisum seeds) in Sailanur Rahem caused by Trichomonas vaginalis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |